Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Get the free reference card Enter your email and we'll send it straight to you
SURPASS-2: Bezporednie porwnanie z selektywnymi agonistami GLP-1 (Semaglutyd)
There are no extra charges
Approximately 19% of people admitted into the trial had heart failure, 23% had experienced previous myocardial infarction or stroke, and 80% were using lipid-lowering drugs
This has been shown in a study published in the Journal of Hormone and Metabolic Research , where participants given recombinant human growth hormone showed an increase in IGF-1 levels and decreased abdominal fat after 26 weeks of treatment: Administration of recombinant human growth hormone (rhGH) in obesity has been known to lead to a decrease in visceral adiposity and an increase in lean body mass
